$29.45-0.34 (-1.14%)
Oscar Health, Inc.
Oscar Health, Inc. in the Healthcare sector is trading at $29.45 with a market capitalization of $6.2B. Wall Street consensus targets $22.60 (10 analysts), implying a -23.3% move over the next 12 months. The stock is currently near its 52-week high of $30.66, remaining 66.7% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.65B↑ | $2.81B↓ | $2.99B↑ | $2.86B↓ | $3.05B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $704.16M↑ | -$353.78M↓ | -$132.43M↑ | -$227.69M↓ | $294.20M |
| Net Income | $679.00M↑ | -$352.61M↓ | -$137.45M↑ | -$228.36M↓ | $275.27M |
Oscar Health, Inc. operates as a healthcare technology company in the United States. The company offers health plans to individuals, families, employees, and small group markets. It also provides +Oscar platform that power others throughout the healt...
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance providers stocks fared in Q1, starting with Oscar Health (NYSE:OSCR).
Oscar Health, Inc. (OSCR) concluded the recent trading session at $29.16, signifying a -2.57% move from its prior day's close.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 5.2% gain for healthcare stocks has fallen short of the S&P 500’s 8.5% rise.
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Investors are still underrating this insurance disrupter.